Recent clinical studies have shown that Bevacizumab, a VEGF inhibitor, can serve as an adjuvant therapy to inhibit tumor angiogenesis, enhance immune system function, and improve both tumor‐free and overall survival in patients with solid tumors, including NSCLC, HCC, and renal cell carcinoma [191, 192, 193, 194, 195]. This evidence concerns the gene VEGFA and neoplasm.